Literature DB >> 2441736

Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer.

F Kirsten, K H Atkinson, J V Coppleson, P M Elliott, D Green, R Houghton, J C Murray, P Russell, H J Solomon, M Friedlander.   

Abstract

Forty-seven patients with locally advanced cervical cancer at high risk of relapse received three cycles of chemotherapy with PVB (cisplatin, vinblastine and bleomycin) before definitive local treatment with either radical surgery or radiotherapy. Thirty-one of the 47 patients (66%) responded to initial chemotherapy, and 11 of them have relapsed compared with 13 of the 16 non-responders. Median time to recurrence was 31 weeks for PVB non-responders but has not yet been reached for PVB responders. After a median follow-up of 128 weeks, 14 of the 31 responders (45%) are alive and disease free compared with 3 of the 16 non-responders (19%). There was a positive correlation between response to chemotherapy and subsequent response to radiotherapy. PVB was in general well tolerated although one death is probably attributable to chemotherapy. A randomized study comparing radiotherapy alone with initial PVB chemotherapy followed by radiotherapy is in progress.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2441736     DOI: 10.1111/j.1471-0528.1987.tb03154.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  4 in total

1.  Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer.

Authors:  J Tobias; E J Buxton; G Blackledge; J J Mould; J Monaghan; D Spooner; A Chetiyawardana
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Changing character of cervical cancer in young women.

Authors:  P M Elliott; M H Tattersall; M Coppleson; P Russell; F Wong; A S Coates; H J Solomon; P M Bannatyne; K H Atkinson; J C Murray
Journal:  BMJ       Date:  1989-02-04

3.  The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix.

Authors:  R P Symonds; R A Burnett; T Habeshaw; S B Kaye; M P Snee; E R Watson
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

4.  Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.

Authors:  G J Rustin; E S Newlands
Journal:  Br J Cancer       Date:  1988-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.